Basal and claudin-low breast cancers present a major clinical challenge, as their frequent triple-negative phenotype (lacking HER2, oestrogen and progesterone receptors) confers intrinsic resistance to HER2-targeted and endocrine therapy [12]. Here, ERBB2 is linked to breast carcinoma.